Founded in February 2021, K36 is a privately held biotech company. Investors include F-Prime Capital, Atlas Venture, and Eight Roads Venture Capital. Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for the benefit of cancer patients worldwide.
